Hay feeder
    6.
    发明授权
    Hay feeder 有权
    干草喂

    公开(公告)号:US08677940B1

    公开(公告)日:2014-03-25

    申请号:US13656472

    申请日:2012-10-19

    IPC分类号: A01K5/01

    CPC分类号: A01K5/008

    摘要: A hay feeder for preventing waste and gluttony. The hay feeder includes a support member being fastened to a structure; a net having a plurality of openings being disposed therethrough and depending from the support member; and a fastener assembly for fastening the support member to the structure.

    摘要翻译: 用于防止浪费和glut y的干草饲料。 干草进料器包括固定在结构上的支撑件; 具有多个开口的网,其穿过并穿过所述支撑构件; 以及用于将支撑构件紧固到结构的紧固件组件。

    Pharmaceutical solid state forms
    7.
    发明授权
    Pharmaceutical solid state forms 有权
    药物固体形式

    公开(公告)号:US08518922B2

    公开(公告)日:2013-08-27

    申请号:US12370510

    申请日:2009-02-12

    IPC分类号: A61K31/567 C07J1/00

    摘要: The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions.

    摘要翻译: 本发明提供并描述了固态17α-乙炔基-5α-雄甾烷-3α,17β-二醇,其包括无定形和结晶形式及其特定的多态形式。 17α-乙炔基-5α-雄甾烷-3α,17β-二醇的水合物和溶剂化物包括III型无水物和I型溶剂合物。 本发明还涉及含有所述固体形式的17α-乙炔基-5α-雄甾烷-3α,17β-二醇的固体和悬浮液制剂,并且该制剂用于治疗受试者或人类中的癌症或前列腺癌如前列腺癌或乳腺癌 耐心。 本发明还涉及从17α-乙炔基-5α-雄甾烷-3α,17β-二醇的固体形式制备液体制剂的方法以及这些制剂在治疗所述病症中的用途。

    PHARMACEUTICAL SOLID STATE FORMS
    8.
    发明申请
    PHARMACEUTICAL SOLID STATE FORMS 有权
    药物固体状态

    公开(公告)号:US20090291932A1

    公开(公告)日:2009-11-26

    申请号:US12370510

    申请日:2009-02-12

    IPC分类号: C07J7/00 A61K31/56 A61P35/04

    摘要: The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions.

    摘要翻译: 本发明提供并描述了固态17α-乙炔基-5α-雄甾烷-3α,17β-二醇,其包括无定形和结晶形式及其特定的多态形式。 17α-乙炔基-5α-雄甾烷-3α,17β-二醇的水合物和溶剂化物包括III型无水物和I型溶剂合物。 本发明还涉及含有所述固体形式的17α-乙炔基-5α-雄甾烷-3α,17β-二醇的固体和悬浮液制剂,并且该制剂用于治疗受试者或人类中的癌症或前列腺癌如前列腺癌或乳腺癌 耐心。 本发明还涉及从17α-乙炔基-5α-雄甾烷-3α,17β-二醇的固体形式制备液体制剂的方法以及这些制剂在治疗所述病症中的用途。